Literature DB >> 9683567

Substrate, inhibitor, or antibody stabilizes the Glu 119 Gly mutant influenza virus neuraminidase.

A Sahasrabudhe1, L Lawrence, V C Epa, J N Varghese, P M Colman, J L McKimm-Breschkin.   

Abstract

We have previously reported the isolation and characterization of an influenza virus variant with decreased sensitivity to the neuraminidase-specific inhibitor zanamivir. This variant, which has a mutation in the active site, Glu 119 Gly (E119G), has the same specific activity as the wild-type neuraminidase (NA), but is inherently unstable, as measured by loss of both enzyme activity and NC10 monoclonal antibody reactivity. However, despite the instability of the NA, replication of the virus in liquid culture is not adversely affected. We demonstrate here that in addition to enhanced temperature sensitivity the mutant NA was significantly more sensitive to formaldehyde and to specimen preparation for electron microscopy. Substrate, inhibitor, or monoclonal antibodies stabilized the NA against all methods of denaturation. These results suggest that the instability of the variant is primarily at the level of polypeptide chain folding rather than at the level of association of monomers into tetramers. Furthermore the presence of high levels of substrate, either cell or virus associated, may be sufficient to stabilize the NA during virus replication.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9683567     DOI: 10.1006/viro.1998.9222

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  6 in total

1.  Thermal denaturation of influenza virus and its relationship to membrane fusion.

Authors:  Richard M Epand; Raquel F Epand
Journal:  Biochem J       Date:  2002-08-01       Impact factor: 3.857

2.  Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.

Authors:  Jennifer L McKimm-Breschkin; Janelle Williams; Susan Barrett; Kim Jachno; Mandy McDonald; Peter G Mohr; Takehiko Saito; Masato Tashiro
Journal:  J Antimicrob Chemother       Date:  2013-06-11       Impact factor: 5.790

Review 3.  Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

Authors:  Jennifer L McKimm-Breschkin
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

4.  Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.

Authors:  J M Barnett; A Cadman; D Gor; M Dempsey; M Walters; A Candlin; M Tisdale; P J Morley; I J Owens; R J Fenton; A P Lewis; E C Claas; G F Rimmelzwaan; R De Groot; A D Osterhaus
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

5.  Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.

Authors:  Aaron J Oakley; Susan Barrett; Thomas S Peat; Janet Newman; Victor A Streltsov; Lynne Waddington; Takehiko Saito; Masato Tashiro; Jennifer L McKimm-Breschkin
Journal:  J Med Chem       Date:  2010-09-09       Impact factor: 7.446

6.  A generic system for the expression and purification of soluble and stable influenza neuraminidase.

Authors:  Peter M Schmidt; Rebecca M Attwood; Peter G Mohr; Susan A Barrett; Jennifer L McKimm-Breschkin
Journal:  PLoS One       Date:  2011-02-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.